Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback